Form 4: United Therapeutics Insider Trades Common Stock
Insider Transaction Report
Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock on May 7, 2026, under a 10b5-1 plan.
Summary
- Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corporation, reported a series of transactions on May 7, 2026.
- These transactions included the exercise of stock options and the subsequent sale of common stock.
- The exercise of stock options involved 8,300 shares at a price of $146.03 per share.
- Following these transactions, Mr. Mahon beneficially owns 45,172 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it represents routine insider transactions under a pre-established plan and does not inherently signal positive or negative performance.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it pertains to insider transactions.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive stock dealings. These filings are crucial for investors monitoring executive confidence and potential shifts in beneficial ownership.
Stakeholder Impact
- Shareholders: Provides transparency into executive stock activity, which can influence investor perception.
- Employees: Indirect impact as executive compensation and stock ownership are part of the corporate structure.
- Creditors: No direct impact indicated.
- Suppliers: No direct impact indicated.
- Customers: No direct impact indicated.
Key Dates
| Date | Description |
|---|---|
| 08/11/2025 | Date of entry into pre-arranged 10b5-1 plan. |
| 05/07/2026 | Date of earliest transaction reported and transaction date for option exercise and stock sales. |
| 03/15/2020 | Stock option grant date. |
| 03/15/2027 | Stock option expiration date. |
Keywords
Form 4, SEC Filing, Insider Trading, Stock Options, Common Stock, United Therapeutics, UTHR, 10b5-1 plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.